Structure Therapeutics (NASDAQ:GPCR) Shares Up 6.6% – Here’s What Happened

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR)’s stock price was up 6.6% on Wednesday . The company traded as high as $37.10 and last traded at $36.7660. Approximately 771,633 shares changed hands during trading, a decline of 17% from the average daily volume of 929,127 shares. The stock had previously closed at $34.50.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on GPCR. Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a report on Wednesday, October 8th. Zacks Research cut Structure Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Friday, October 17th. Lifesci Capital raised Structure Therapeutics to a “strong-buy” rating in a report on Monday, September 8th. Piper Sandler restated an “overweight” rating on shares of Structure Therapeutics in a research note on Tuesday, October 28th. Finally, HC Wainwright dropped their target price on Structure Therapeutics from $75.00 to $60.00 and set a “buy” rating on the stock in a research report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $68.67.

Structure Therapeutics Trading Up 10.8%

The stock has a market cap of $2.21 billion, a P/E ratio of -31.46 and a beta of -1.63. The stock’s 50-day moving average is $28.44 and its 200-day moving average is $23.46.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.01). On average, equities analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current year.

Hedge Funds Weigh In On Structure Therapeutics

Several hedge funds have recently modified their holdings of GPCR. EverSource Wealth Advisors LLC lifted its holdings in shares of Structure Therapeutics by 530.0% in the third quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock valued at $30,000 after buying an additional 901 shares during the period. State of Wyoming bought a new stake in Structure Therapeutics in the second quarter worth about $28,000. Assetmark Inc. lifted its holdings in Structure Therapeutics by 39.9% in the 2nd quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock valued at $60,000 after acquiring an additional 820 shares during the last quarter. National Bank of Canada FI boosted its position in shares of Structure Therapeutics by 1,448.2% during the 1st quarter. National Bank of Canada FI now owns 2,957 shares of the company’s stock valued at $51,000 after purchasing an additional 2,766 shares in the last quarter. Finally, ANTIPODES PARTNERS Ltd boosted its position in shares of Structure Therapeutics by 39.1% during the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company’s stock valued at $114,000 after purchasing an additional 1,146 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.